Status:
COMPLETED
Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice
Lead Sponsor:
Tanta University
Conditions:
Hepatobiliary Disorders
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-he...
Eligibility Criteria
Inclusion
- Patients age 18-70 years old.
- Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL.
Exclusion
- Pregnancy.
- Nursing mothers.
- Patients with increased indirect bilirubin level.
- Patients who have Gilbert syndrome or Crigler Najjar syndrome.
- Patients with Child Paugh C score (10-15 point).
- History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline.
- Recent hemorrhage.
- Patients who have risk factors potentially complicated by hemorrhage.
- Taking anticoagulants or antiplatelet therapy.
Key Trial Info
Start Date :
April 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2025
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT06944704
Start Date
April 3 2024
End Date
March 19 2025
Last Update
July 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy, Tanta University
Tanta, Egypt, 31111